Sustained anti-pruritic effect in mice with TP-2021, a kappa opioid agonist peptide, delivered by subdermal ProNeura® Implants (Video)
Presented at the Society for Neuroscience, November 2021.
Posters
Sustained anti-pruritic effect in mice with TP-2021, a kappa opioid agonist peptide, delivered by subdermal ProNeura® Implants (PDF)
Presented at the Society for Neuroscience, November 2021.
Evaluation of Drug-Drug Interaction Potential of Probuphine® Implants using a Physiologically-Based Pharmacokinetic Model
Presented by Titan Pharmaceuticals at the 10th American Conference on Pharmacometrics in Orlando, Florida, October 2019.
Population Pharmacokinetic Modeling and Exposure-Response Analysis of Probuphine® Implants in Opioid Use Disorder Subjects
Presented by Titan Pharmaceuticals at the 10th American Conference on Pharmacometrics in Orlando, Florida, October 2019.
Developing Long-Term Malarial Chemoprophylactic Compound Releasing Implants
Presented at the American Society of Tropical Medicine & Hygiene Annual Meeting in Baltimore, Maryland, November 2017.
Long-Term Sustained Delivery Of Liothyronine (L-T3) With Subdermal ProNeura™ Implants
Presented at the 87th Annual Meeting of the American Thyroid Association in Victoria, Canada, October 2017.
Developing Long-term Malarial Chemoprophylactic Compound Releasing Implants
Presented at the Asia Pacific Military Health Exchange (APMHE), Singapore, May 2017.
Continuous Delivery of Ropinirole by Subdermal ProNeura™ Implants
Presented at the Movement Disorders Society 19th International Congress of Parkinson's Disease and Movement Disorders in San Diego, California, June 2015.
Buprenorphine Implants for the Maintenance Treatment of Opioid Dependence: Twelve Month Outcomes
Presented at the American Association for the Treatment of Opioid Dependence conference in Philadelphia, Pennsylvania, November 2013.
Results of a Six-Month, Randomized, Controlled, Phase-3 Trial Comparing the Efficacy and Safety of Buprenorphine Implants to Placebo Implants, and Sublingual Buprenorphine/Naloxone for Opioid Addiction.
Presented at the American Society of Addiction Medicine (ASAM), Atlanta, Georgia, April 2012.